By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Estimating Lifetime or Episode-of-Illness Costs Under Censoring
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Estimating Lifetime or Episode-of-Illness Costs Under Censoring
Public Health

Estimating Lifetime or Episode-of-Illness Costs Under Censoring

JasonShafrin
JasonShafrin
Share
5 Min Read
SHARE

How can you estimate an individual’s total lifetime cost of medical care? For people who die in your sample, this is simple. In most data sets, however, not all individuals will die during the period of observation. Thus, the data set is censored for those who do not die. In addition, many standard hazard models do not allow for researchers to disaggregate the effects of covariates on survival and the intensity of utilization. Both factors have an effect on cost. Assuming that censoring is random, Basu and Manning (2010) describe a method to calculate expected lifetime costs for each individual as follows:

  1. Estimate Survival Probabilities. Use a flexible survival model, such as an accelerated failure time model based on the generalized gamma distribution for time, to estimate the individual’s survival function after taking into account censoring. Let Sj(X) and hj(X) be the estimated survivor function and the hazard function for an interval indexed by j. The observation The predictions are obtained for all time periods for all patients.
  2. Estimate cost among patients who died. Among those subject intervals, (aj-1, aj], where we observe the subject to die, estimate a generalized linear model (or models if a two-part specification is necessary) for the observed costs after conditioning on covariates X. One can also condition on the time of death within the interval as well. Use parameter estimates from this model to predict costs, μ1j(X), for every subject-interval in the data. To account for the stochastic nature of U within that interval (i.e. to account for what would the costs be if the patient died inside that interval but at different times), one simply averages the predictions that are conditional of each value of U after weighting with the observed distribution of U among intervals where patients are observed to die. Therefore, μ1j(X)=∫μ1j(X,U) dF(U|abobsb+1).
  3. Estimate the cost among subjects not observed to die. Next, among those subject intervals, (aj-1, aj], where patients are not observed to die but excluding those where we only observe costs over a partial duration due to censoring, estimate a generalized linear model (or models if a two-part specification is necessary) for the observed cost functions after conditioning on covariates X. We use parameter estimates from this model to predict costs, μ2j(X), for every subject-interval in our data. We do not use the subject intervals where censoring occurs in our estimation in this part. This allows us effectively to allow for continuous censoring times.

  Thus, the resulting cost function for interval j for any individual is given by:

  • μj(X)=Sj(X)*[hj(X)*μ1j(X) + (1-hj(X))*μ2j(X)]

  There are a number of benefits of using this framework. First, Basu and Manning show that this estimator can “decompose the covariate effects on total costs into part mediated by survival effects and another mediated by intensity of use.” Second, this method allows for death to take place any time during each interval rather than solely at the end of an interval. Third, the model “allows for separate estimators to be used for end-of-life and non-end-of-life periods.” The separate estimators are especially useful in cases where end-of-life cost differs significantly from the regular course of care. For instance, one study demonstrated the there is a U-shaped pattern of cost history among cancer patients with the left side of the U corresponding to initial treatment and the right side reflecting a substantial spike in costs during the last 6 months of life. For those interested, Basu and Manning also provide a simulation and empirical application to demonstrate the utility of their econometric specification compared to earlier models.

TAGGED:medical costs
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Clinical and Interpersonal Skills That Define Excellence in Patient-Centered Care
Health
June 2, 2026
The Advanced Nursing Credentials That Open Doors to Leadership Roles
The Advanced Nursing Credentials That Open Doors to Leadership Roles
Nursing
June 2, 2026
The Advanced Practice Nursing Roles Worth Knowing About Before You Specialize
The Advanced Practice Nursing Roles Worth Knowing About Before You Specialize
Nursing
June 2, 2026
Language Access in Healthcare: What Hospitals Still Get Wrong in 2026
Hospital Administration Technology
May 29, 2026

You Might also Like

Public Health

Non-Fatal Strangulation: What Patients and Providers Must Know

April 30, 2012
DiagnosticsPublic HealthWellness

Women Must Regulate Hormone Levels to Stop Gum Disease

April 13, 2017
ACA health reform
BusinessHealth ReformHospital AdministrationPolicy & LawPublic Health

Health Reform Beyond the ACA: Are We Inching Towards Consensus?

October 27, 2013

Getting Young Invincibles to Buy Health Insurance?

March 16, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?